nectin 4 urothelial

Summary

Nectin-4 is a tumor-associated antigen overexpressed in urothelial carcinoma and several other malignancies 1 , and has been identified as a compelling target for novel tumor-directed therapies, particularly as a component of antibody-drug conjugates (ADCs). 1 The U.S. Food and Drug Administration has granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate 2 , which specifically targets cancer cells expressing Nectin-4. 2

According to
1 pubmed.ncbi.nlm.nih.gov 2 www.fda.gov


See more results on Neeva

Summaries from the best pages on the web

Enfortumab vedotin-ejfv is the first Nectin - 4 -directed antibody-drug conjugate to receive FDA approval. Efficacy was investigated in EV-201 (NCT03219333), a single-arm, multicenter trial enrolling ...
FDA grants accelerated approval to enfortumab vedotin-ejfv for ...
favIcon
fda.gov
Urothelial carcinoma is the most common type of bladder cancer and accounts for 90% of bladder cancer cases in the USA and Europe. Novel approaches are needed to improve patient…
The biology and rationale of targeting nectin-4 in urothelial ... - PubMed
favIcon
nih.gov
The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 in morphologic variants of urothelial carcinoma and…
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic ...
favIcon
nih.gov
Summary Today, the U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers
FDA approves new type of therapy to treat advanced urothelial cancer
favIcon
fda.gov
An antibody-drug conjugate (ADC), enfortumab vedotin exploits the high levels of nectin - 4 expression in urothelial carcinoma to enable targeted deployment of a cytotoxic warhead in tumor...
Nectin-4 Emerges as a Therapeutic Target in Urothelial ... - OncLive
favIcon
onclive.com
NECTIN - 4 / NECTIN - 4 expression was higher in luminal tumors and reduced in squamous aUCs. NECTIN - 4 was negative in 10.6% of samples, and 18. 4 % of samples had low expression (H-Score < 15). TROP2…
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular ...
favIcon
ascopubs.org
Enfortumab vedotin (EV), an antibody–drug conjugate targeting NECTIN4, was recently approved for treatment-refractory metastatic urothelial cancer. NECTIN4 is a cell surface protein implicated in cell–cell adhesion and thought to be…
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of ...
favIcon
aacrjournals.org
However, expression of nectin - 4 in morphologic variants of urothelial carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for nectin - 4 using was performed on 169 patients including 83 with nonmuscle invasive bladder…
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in M ... - LWW
favIcon
lww.com